转移性去势抵抗性前列腺癌的强化治疗策略与治疗顺序:一项系统综述
本系统综述遵循PRISMA-P指南,检索截至2024年5月15日的文献,纳入28项临床试验和24项正在进行的研究,总结转移性去势抵抗性前列腺癌(mCRPC)的强化治疗策略与序贯治疗证据。文章根据既往是否使用雄激素受体通路抑制剂(ARPI)和/或多西他赛勾勒了已批准治疗的最佳序贯算法,并讨论了正在进行的强化治疗研究及预测和预后生物标志物。
要点
- 一线PARP抑制剂+ARPI联合改善影像学无进展生存期,尤其对BRCA1/2改变者。
- AKT抑制剂组合伊帕他尼+阿比特龙在PTEN缺失或PIK3CA/AKT1/PTEN改变者中延长rPFS。
- 恩扎卢胺治疗早期进展风险因素≥2个者,177-Lu-PSMA-617+恩扎卢胺延长无进展生存期。
核心结论
- 近期单药及强化治疗方案的批准和正在进行的探索将持续改变mCRPC的治疗格局。
- 应用公认的基因组、分子和临床预测及预后指标改进患者特征分析,对于优化现有治疗的序贯使用至关重要。
研究设计与样本
- 遵循PRISMA-P指南进行的系统综述,检索PubMed、EMBASE、Web of Science、Cochrane Library、ClinicalTrials.gov及主要国际学会在线会议资料,截至2024年5月15日。
- 共纳入28项临床试验和24项正在进行的强化治疗研究。
主要发现
- 一线PARP抑制剂+ARPI联合改善影像学无进展生存期(rPFS),尤其对BRCA1/2改变者。
- AKT抑制剂组合伊帕他尼+阿比特龙在PTEN缺失或PIK3CA/AKT1/PTEN改变者中延长rPFS。
- 对恩扎卢胺治疗早期进展风险因素≥2个者,放射性核素177-Lu-PSMA-617+恩扎卢胺延长无进展生存期。
- 根据既往是否使用ARPI和/或多西他赛,勾勒了已批准治疗用于mCRPC的最佳序贯算法。
临床怎么用
- 作者指出,应用公认的基因组、分子和临床预测及预后指标改进患者特征分析,对于优化现有治疗的序贯使用至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Recently, research on treatment intensification has gathered momentum, and three novel therapy combinations were approved for metastatic castration-resistant prostate cancer (mCRPC). This systematic review summarizes the current and emerging evidence around intensified strategies for mCRPC and provides guidance for an ideal therapeutic sequencing. METHODS: Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines were followed to perform this review. PubMed, EMBASE, Web of Science, Cochrane Library, ClinicalTrials.gov, and major international societies' online proceedings were searched comprehensively until May 15, 2024, for terms related to treatment intensification and sequencing for mCRPC. KEY FINDINGS AND LIMITATIONS: Overall, 28 clinical trials and 24 ongoing studies of intensification treatments were included in this review. Algorithms of optimal sequencing of approved treatments for mCRPC were outlined according to the use of androgen receptor pathway inhibitors (ARPIs) with or without docetaxel for earlier disease states. In first line, poly(ADP-ribose) polymerase inhibitor + ARPI combinations improve radiographical progression-free survival (rPFS), particularly for those with BRCA1/2 alterations. The AKT inhibitor combination of ipatasertib + abiraterone extends rPFS in those with PTEN loss or PIK3CA/AKT1/PTEN alterations. In those with two or more risk factors for early progression on enzalutamide, radionuclide 177-Lu-PSMA-617 + enzalutamide prolongs progression-free survival. Ongoing research of intensified approaches for mCRPC, and available and potential predictive and prognostic biomarkers are discussed. CONCLUSIONS AND CLINICAL IMPLICATIONS: Recent approvals and ongoing investigations of single agents and intensification approaches will keep transforming the mCRPC treatment landscape. Improvement of patient profiling applying recognized genomic, molecular, and clinical predictive and prognostic indicators is fundamental to optimize sequential use of available therapies.
引用
- Francini E, Agarwal N, Castro E, et al. Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review. Eur Urol. 2024. PMID: 39306478. doi:10.1016/j.eururo.2024.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。